

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

801/2019	Results for assessment
COELIAC DISEASE	53
Total distributed	53
Total submitted	53
Reference	DQA1*02:01,*04:01; DOB1*02:02,*04:02
Number acceptable	44
Number unacceptable	4
Assessed @	2

Lab Results for assessment	Alleles of interest	Interpretative comments	Comments	Received	Tested	Assessment
11 HLA-DQ2 positive	DOB1*02; DOB1*03:02	The presence of HLA-DQ2 is associated with, but not diagnostic for, coeliac disease. HLA-DQ2 is present in about 21% of caucasians in the normal population		09/04/2019	16/04/2019	Acceptable
12 DQ2: Positive, DQ8: Negative, DQA1*05: Negative	DQ2, DQ8, DQA1*05	This patient is negative for both the DQA1*05/DQB1*02 heterodimer and DQB1*03:02 which are present in over 95% patients with coeliac disease. However, this patient is positive for DQB1*02, which comprises one half of the DQA1*05/DQB1*02 heterodimer, present in 2-5% of patients with coeliac disease. This genotype has been associated with genetic susceptibility for coeliac disease.		10/04/2019	12/04/2019	Acceptable
15 Not Tested				0000-00-00	0000-00-00	Not assessed
17 DQA1*05:01 DQB1*02:01 (cis) - DQ2 Negative DQA1*05:05:02:01 DBQ1*03:01:02:02 (trans) - DQ2 Negative DQA1*03:01 DQB1*03:02 - DQ8 Negative	DQA1*05:01 DQB1*02:01 (cis) DQA1*05:05:02:01 DBQ1*03:01:02:02 (trans) DQA1*03:01 DQB1*03:02	The major association for Coeliac disease involves the haplotype: DQA1*05:01 & DQB1*02:01 (DQ2) and a minority of cases with the haplotype: DQA1*03:01 & DQB1*03:02 (DQ8). (Nature Reviews Immunology 2002:2:647) This patient is NEGATIVE for the DQA1*05:01-DQB1*02:01 (DQ2) haplotype and DQA1*03-DBQ1*03:02 (DQ8) haplotype. This patient has no genetic risk of having or developing coeliac disease.		11/04/2019	12/04/2019	Unacceptable
24 DOB1*02:02/06/10/11/12,*04:02/20/27/31; DQA1*02:01,*04:01/03N/04	DOB1*02, DQA1*05, DOB1*03:02	The patient possesses only one allele of the Coeliac Disease associated HLA-DQ2 molecule: DQB1*02 (DQA1*05 is not present). Patients with this genotype have a low risk of predisposition to Coeliac Disease. Other clinical indications are required for diagnosis.		10/04/2019	15/04/2019	Acceptable
25 DQB1*02:02,*04:02, DQA1*02:01,*04:01	DQ2 DQ8	This patient is DQ2.2 positive, heterozygous. This patient is DQ2 positive which is associated with Coeliac Disease.		10/04/2019	18/04/2019	Acceptable
38 DQB1*02:02,*04:02 DQA1*02:01,*04:01	DOB1*02 and DOB1*03:02	This individual carries the DOB1*02:02 (DQ2) variant that has a weak association with coeliac disease (Low risk).		10/04/2019	18/04/2019	Acceptable
42 DQA1*02:01 DQA1*04:01/04:03N/04:04 DOB1*02:02/06/10/11/12/26/50/62/64/65/80/84/89/95/97/103/104 DOB1*04:02/04:04/04:11/04:13/04:18/04:19/04:23/04:24/04:25N/04:26/04:29/04:32/04:33/04:34/04:35/04:36N/04:37/04:39/04:40/04:41N/04:43/04:44/04:45/04:46N/04:47/04:48	HLA-DQ	This patient is Heterozygous POSITIVE for HLA-DQ2 (but is DQA1*05 NEGATIVE) and NEGATIVE for HLA-DQ8 (DOB1*03:02). Patients with this genotype have a LOW RISK of predisposition to Coeliac disease		11/04/2019	12/04/2019	Acceptable
78 Not tested				10/04/2019	0000-00-00	Not assessed
85 DQA1*05 negative DOB1*02 positive DOB1*03:02 negative	DQA1*05 DOB1*02 DOB1*03:02	This individual does not have the HLA-DQ variants associated with coeliac disease. This assay tests for the presence of HLA-DQ2 (DQA1*05/DQB1*02) and HLA-DQ8 (DOB1*03:02) which are found in more than 97% of patients with coeliac disease. However, 2-3% patients with coeliac disease have a rare genotype that is not detected by this assay.		10/04/2019	23/04/2019	Acceptable
86 Coeliac disease-associated HLA alleles present: DOB1*02:02 DQA1*02:01 HLA-DQ2: PRESENT - HLA-DQ2.2 HLA-DQ8: ABSENT	DQ2 and DQ8 associated DOB1* and DQA1*	HLA-DQ2.2, which is associated with low genetic susceptibility for coeliac disease (CD), has been detected in heterozygous form in this patient. As 25-30% of the general population has one of the CD-associated HLA alleles encoding DQ2 and/or DQ8 and only 3% of these individuals develop coeliac disease, identification of a CD-associated HLA allele is not diagnostic of CD. The presence of DQ2 and/or DQ8 increases the likelihood that the patient has CD but a diagnosis must be based on clinical findings, serum antibody detection tests and/or intestinal biopsy.		10/04/2019	23/04/2019	Acceptable
87 positive heterozygous for HLA-DQ2.2 and P subunit HLA-DQ2.2/DQ2.5, rest negative	HLA-DQ2.2, HLA-DQ 2.5, HLA-DQ8, Beta subunit HLA-DQ2.2/DQ2.5	90-95% of Coeliac patients are HLA DQ2 or DQ8 positive (Husby S, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr. 2012; 54:13660).		10/04/2019	24/04/2019	Acceptable
109 DQA1*05: negative DOB1*02:01 / DOB1*02:02: positive DOB1*03:02 (DQ8): negative	DQA1*05 DOB1*02:01 / DOB1*02:02 DOB1*03:02 (DQ8)	There is no associated risk for coeliac condition		10/04/2019	16/04/2019	Acceptable
113 Haemolysis of the sample. No result available	DQ2 and DQ8		Haemolysis of the sample. DNA concentration too low and bad quality. No result available	09/04/2019	0000-00-00	Not assessed
123 Not Tested				0000-00-00	0000-00-00	Not assessed
124 Not Tested				0000-00-00	0000-00-00	Not assessed
126 DQA1*05=NEG, DQB1*02=POS, DQA1*02=POS, DQA1*03=NEG, DQB1*03:02=NEG	DQA1*05, DQB1*02, DQA1*02, DQA1*03, DQB1*03:02			10/04/2019	15/04/2019	Acceptable
127 HLA-DQ2*2 positive, HLA-DQ8* negative	HLA-DQA1* HLA-DQB1* DOB1*02,*03:02; DQA1*05	Slightly increased risk for coeliac disease		11/04/2019	16/04/2019	Acceptable
129 DOB1*02 positive, DOB1*03:02 negative, DQA1*05 negative	HLA-DQA1*05, HLA-DQB1*02 and HLA-DQB1*03:02 (DQ8)	Présence de l'alle`le HLA-DQB1*02 (DQ2) mais absence des all`eles HLA-DQA1*05 et DQB1*03:02 (DQ8). Risque faible de pr`edisposition `a` la maladie c`eli`a`que.		22/04/2019	29/04/2019	Acceptable
142 HLA-DQA1*05 absent HLA-DQB1*02 present HLA-DQB1*03:02 (DQ8) absent		Absence of alleles DQB1*02:01-DQA1*05:01 and DQB1*03:02-DQA1*03:01		17/04/2019	18/04/2019	Acceptable
150 DOB1*02:02 ; *04:02 DQA1*02:01:04:01	DQ2 - DOB1*02:01-DQA1*05:01 DQ8 - DOB1*03:02-DQA1*03:01			10/04/2019	17/04/2019	Acceptable
154 HLA-DQA1*02:01,*04:01; HLA-DQB1*02:02,*04:02	HLA-DQA1* and HLA-DQB1* are typed to the 4-digit level to determine whether HLA-DQ2 is coded by DQA1*05:01, DQB1*02:01 ; HLA-DQ2 is coded by DQA1*05:05, DQB1*03:01 and DQA1*02:01, DQB1*02:02 ; HLA-DQ8 is coded by DQA1*03:01, DQB1*03:02	haplotype DQA1*05:01, DQB1*02:01 - absence haplotypes DQA1*05:05, DQB1*03:01 and DQA1*02:01, DQB1*02:02; absence haplotype DQA1*03:01, DQB1*03:02 - absence	The patient has HLA-DQ2 encoded by a haplotype not listed to be most at risk of coeliac disease. >95% of coeliac disease patients express HLA-DQ2 encoded by DQA1*05:01, DQB1*02:01 or DQA1*05:05, DQB1*03:01 and DQA1*02:01, DQB1*02:02. 5% of coeliac disease patients express HLA-DQ8 encoded by DQA1*03:01, DQB1*03:02. HLA-DQ2 or DQ8 are expressed in 30-40% of the Caucasian population. HLA typing has a good negative predictive value in the diagnosis of coeliac disease.			

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

159 DQA1*03 negative, DQA1*05 negative, DOB1*02 positive and DOB1*03.02 negative	DQA1*03, DQA1*05, DOB1*02 and DOB1*03.02	Absence of susceptibility phenotype for coeliac disease	11/04/2019	12/04/2019	Acceptable
173 DQA1*05NEGATIVE DOB1*02POSITIVE DQA1*03 NEGATIVE DOB1*03.02 NEGATIVE DOB1*03.03 NEGATIVE	HLA-DQA1*05, HLA-DQA1*03, HLA-DOB1*02, HLA-DOB1*03.02, HLA-DOB1*03.03	Low risk of coeliac disease	17/04/2019	23/04/2019	Acceptable
176 DQA1*05-Pos DOB1*02-Pos DOB1*03.02-Neg	DQA1*05 DOB1*02 DOB1*03.02	Celiac tissue type examination: Positive for HLA-DQB1 * 02 (DQ2), HLA-DQA1 * 05 and negative for HLA-DQB1 * 03: 02 (DQ8). The genetic risk of Celiac disease is present.	15/04/2019	16/04/2019	Unacceptable
201 DQA1*02.01 DQA1*04.01 DOB1*02.02 DOB1*04			10/04/2019	17/04/2019	Acceptable
219 DOB1*03.02: negative DQA1*05: negative DOB1*02: positive DQA1*02: positive Reported serotype: DQ2.2	HLA-DOB1*03.02, HLA-DQA1*05, HLA-DOB1*02, HLA-DQA1*02	English translation: "HLA-DQ2.2 is detected in the form of HLA-DQB1*02 and HLA-DQA1*02. A small minority of coeliac patients has these alleles. The alleles are common in the general population. Coeliac disease is unlikely. However, the test alone can not exclude coeliac disease."	24/04/2019	30/04/2019	Acceptable
223 DQA1*02 positive, DQA1*03 negative, DQA1*05 negative, DOB1*02 positive, DOB1*03.02 negative	DQA1*02, DQA1*03, DQA1*05, DOB1*02, DOB1*03.02		10/04/2019	16/04/2019	Acceptable
224 DQA1*05=NEG; DOB1*02=POS; DOB1*03:02 group (DQ8)= NEG 225 DQ2-positive, DQ8-negative	DQA1*02, DQA1*03, DQA1*05 DOB1*02, DOB1*03.02	The patient is HLA-DQ2.2 positive. Coeliac disease is associated with this HLA-type in 5%.	10/04/2019 15/04/2019	17/04/2019 17/04/2019	Acceptable Acceptable
245 DOB1*02*04; DQA1*02*04	DOB1*02=DQA1*05 DOB1*02 DOB1*03.02	Presence of DQ2 antigen not associated with an alpha chain at risk: low to very low risk to develop coeliac disease. This result alone does not confirm the diagnosis.	10/04/2019	17/04/2019	Acceptable
255 DOB1*02 pos	DQA1*05, DOB1*02, DOB1*03.02	DQ2.5 neg DQ8 neg	10/04/2019	23/04/2019	Acceptable
263 DQA1*0201 present, DQA1*03 absent, DQA1*05 absent DOB1*02 present (heterozygous), DOB1*0302 absent	HLA-DQA1*0201, DQA1*03, DQA1*05 HLA-DOB1*02, DOB1*0302 Homozygous or heterozygous status for DOB1*02 only	The HLA-DQB1 * 02 allele is present in heterozygosity. This condition, while compatible with the presence of coeliac disease, has not been shown to significantly increase the risk of disease compared to the general population.	18/04/2019	23/04/2019	Acceptable
269 positive	HLA DQ2.2 HLA DQ2.5 HLA DQ8	HLA DQ2.2 positive, heterozygot HLA DQ2.5 negative HLA DQ8 negative	07/04/2019	17/04/2019	Acceptable
274 HLADQ2trans, haplotype2 carrier (detected:DQA1*02, DOB1*02, DRB1*07)	HLADQ2cis, HLADQ2trans, HLA DQ2trans hp1, HLADQ2trans hp2, HLA DQ8		12/04/2019	15/04/2019	Acceptable
276 DQA1*05 negative, DOB1*02 positive, DOB1*03.02 negative	DQA1*05 DOB1*02 DOB1*03.02		10/04/2019	23/04/2019	Acceptable
278 Positive for genotype HLA-DQ2.2	DQA1*02, DQA1*02*0301, DQA1*03, DQA1*0302/03, DQA1*05, DOB1*02, DOB1*02	The genotype indicates a risk of developing coeliac disease	15/04/2019	25/04/2019	Acceptable
279 Not Tested			0000-00-00	0000-00-00	Not assessed
281 Positive association with coeliac disease. DQA1*02:01-DOB1*02:02 type	DQA1* DOB1*		09/04/2019	16/04/2019	Acceptable
307 DQA1*02:01*04:01 DOB1*02*04	DQA1*02 DQA1*05 DQA1*03 DOB1*02 DOB1*03.02	Presence of just the beta chain of the DQ2 dimer (DOB1*02 positive - DQA1*05 negative).	10/04/2019	12/04/2019	Acceptable
315 POSITIVE (DOB1*02, DOB1*04)	DOB1*02, DOB1*03.02		10/04/2019	16/04/2019	Acceptable
317 Positive for allele: DQA1x02, DQA1x02x0301, DOB1x02, DOB1x02x0302	HLA DQA1 and HLA DQB1	Positive for HLA DQ 2.2	15/04/2019	17/04/2019	Unacceptable
319 DQ2 Neg DQ8 Neg	DQA1*05 Neg DOB1*02 Pos DOB1*0302 Neg		10/04/2019	12/04/2019	Unacceptable
331 DOB1*02.02, DOB1*04.02	DOB1*02:01, DOB1*03:02	Absence of DOB1*02:01 ; absence of DOB1*03:02	12/04/2019	24/04/2019	Acceptable
333 DOB1*02, DQA1*02, BRB1*07	DQA1*05, DQA1*02, DQA1*03, DOB1*02, DOB1*0301, DOB1*0302, DRB1*03, DRB1*11, DRB1*12, DRB1*07, DRB1*04		04/04/2019	18/04/2019	Acceptable
338 HLA-DQB1*02:02:DQA1*02:01:DRB1*07	HLA-DQB1; DQA1 ;DRB1*03,*04,*07,*11	Presence of DQ2.2 (DR7/66'DQ2) haplotype in heterozygous state . This condition has been shown to confer a certain, but lower risk to Coeliac Disease.	11/04/2019	28/05/2019	Acceptable
339 Found DOB102 positive, but a genetic predisposition for Coeliac Disease is unlikely	DQA105, DOB102 and DOB10302		10/04/2019	16/04/2019	Acceptable
346 HLA-DQA1*05-NEG, HLA-DOB1*02-POS, HLA-DOB1*03:02P (DQ8)-NEG 347 HLA-DQ2.5-negative, HLA-DQ2.2-positive, HLA-DQ8-negative	DQA1*05, DOB1*02, DOB1*03:02P (DQ8) HLA-DQA1 / HLA-DQB1	Increased risk for the development of Coeliac Disease; determination of serological parameters or biopsy from the small intestine recommended. The patient has a genetic disposition to develop coeliac disease. Analyzing for coeliac antibodies in plasma is recommended.	16/04/2019 16/04/2019	23/04/2019 17/04/2019	Acceptable Acceptable
355 HLA-DQ2.2 Positive			10/04/2019	30/04/2019	Acceptable
359 Alleles positive: DQA1*02, DQA1*01*04*06, DQA1*02*03:01, DOB1*02, DOB1*04*05, alpha-subunit HLA-DQ2.2, beta-subunit HLA-DQ2.2/DQ2.5	DQA1*02, DQA1*03, DQA1*05, DQA1*01*04*06, DQA1*02*03:01, DQA1*03:02/03, DOB1*02, DOB1*03:02, DOB1*03*06, DOB1*04*05, alpha-subunitHLA-DQ2.2, alpha-subunitHLA-DQ2.5, alpha-subunitHLA-DQ8, beta-subunitHLA-DQ2.2/DQ2.5, beta-subunit HLA-DQ8	HLA-DQ2.2: positive, heterozygous beta-subunit HLA-DQ2.2/DQ2.5: positive, heterozygous	11/04/2019	17/04/2019	Acceptable
363 HLA DQ2.2 = Present ; HLA DQ2.5 = Absent ; HLA DQ8 = Absent	DQA1*02, DQA1*02*0301, DQA1*03, DQA1*0302/03, DQA1*05, DOB1*02, DOB1*02*0302		09/04/2019	16/04/2019	Acceptable
413 Presence of DQ2 beta chain (DQA1*02:01; DOB1*02:02; DRB1*07)	DQ2, DQ8 based on the results of DQA1*05:01; DQA1*05:05; DQA1*02:01; DQA1*03; DOB1*02:02; DOB1*02:01; DOB1*03:02; DRB1* detected alleles (allelic groups):		10/04/2019	15/04/2019	Acceptable
1350 DQ2.2 (DQ2 trans haplotype (Hp2) carrier)	HLA-DQ2 cis (DQ2.5): DQA1*05-DQB1*02-DRB1*03 HLA-DQ2 trans (DQ2.5): DQA1*05-DQB1*03:01-DRB1*11/DRB1*12 DQA1*02-DOB1*02-DRB1*07 HLA-DQ2 trans haplotype (Hp1) carrier: DQA1*05-DQB1*03:01-DRB1*11/DRB1*12 HLA-DQ2 trans haplotype (Hp2) carrier (DQ2.2): DQA1*02-DQB1*02-DRB1*07 DQ8:DQA1*03-DQB1*03:02-DRB1*04	detected HLA genotype is associated with the rare risk of coeliac disease	10/04/2019	16/04/2019	Acceptable

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

801/2019
NARCOLEPSY
Total distributed 21
Total submitted 21
Reference DQB1*02:02;DQB1*04:02
Number acceptable 19
Number unacceptable 1
Assessed 19

Lab	Results for assessment	Alleles of interest	Interpretative comments	Comments	Received	Tested	Assessment
11	DQB1*06:02 Negative	DQB1*06:02	HLA-DQB1 allele known to be associated with Narcolepsy is not present		09/04/2019	16/04/2019	Acceptable
12					10/04/2019	12/04/2019	Not assessed
15	Not Tested				0000-00-00	0000-00-00	Not assessed
17	DQB1*06:02- Negative	DQB1*06:02 allele	This patient is NEGATIVE for the narcolepsy associated allele DQB1*06:02.		11/04/2019	12/04/2019	Acceptable
24	DQB1*02:02/06/10/11/12, *04:02/20/27/31; DQA1*02:01, *04:01/03N/04	DQB1*06:02	HLA-DQB1*06:02 is associated with narcolepsy-cataplexy. This patient is NEGATIVE for HLA-DQB1*06:02.		10/04/2019	15/04/2019	Acceptable
25	DQB*06:02 NEGATIVE	DQB*06:02			10/04/2019	18/04/2019	Acceptable
38	DQB1*02:02, *04:02	DQB1*06:02	The patient does not carry the associated HLA alleles which confer susceptibility to Narcolepsy.		10/04/2019	18/04/2019	Acceptable
42	DQB1*02:02/06/10/11/12/26/50/62/64/65/60/84/89/95/97/103/104 DQB1*04:02/04:04/04:11/04:13/04:18/04:19/04:23/04:24/04:25N/04:26/04:29/04:32/04:33/04:34/04:35/04:36N/04:37/04:39/04:40/04:41N/04:43/04:44/04:45/04:46N/04:47/04:48	HLA-DQB1*06:02	DQB1*06:02 NEGATIVE. Narcolepsy is associated with the expression of the human leukocyte antigen (HLA) class II molecule DQB1*06:02.		11/04/2019	12/04/2019	Acceptable
78					10/04/2019	0000-00-00	Not assessed
85					10/04/2019	23/04/2019	Not assessed
86					10/04/2019	23/04/2019	Not assessed
87					10/04/2019	24/04/2019	Not assessed
109	DQA1*01:02: negative DQB1*06:02: negative	DQA1*01:02 DQB1*06:02	There is no associated risk for narcolepsy condition		10/04/2019	16/04/2019	Acceptable
113	Haemolysis of the sample. No result available	DQB1*06:02		Haemolysis of the sample, DNA concentration too low and bad quality. No result available	09/04/2019	0000-00-00	Not assessed
123					0000-00-00	0000-00-00	Not assessed
124					0000-00-00	0000-00-00	Not assessed
126					10/04/2019	15/04/2019	Not assessed
127	HLA-DQB1*06:02 negative	HLA-DQB1*06:02	Risk for narcolepsy not increased		11/04/2019	16/04/2019	Acceptable
129	DQB1*06:02 negative	DQB1*06:02			22/04/2019	28/04/2019	Acceptable
142	HLA-DQB1*06:02 absent	HLA-DQB1*06:02	Absence of allele DQB1*06:02.		11/04/2019	22/04/2019	Acceptable
150	DQB1*02:04.	DQB1*06:02			17/04/2019	18/04/2019	Acceptable
154	HLA-DQB1*02:02,*04:02	HLA-DQB1*06:02	Allele DQB1*06:02 : absence		10/04/2019	17/04/2019	Acceptable
159	DQB1*06:02 negative, DQA1*01:02 negative	DQB1*06:02, DQA1*01:02	The HLA-DQB1*06:02 is found in 15-25% of the overall population and in 90-100% of narcolepsy patients.	Absence of susceptibility phenotype for narcolepsy	11/04/2019	12/04/2019	Not assessed
173					17/04/2019	23/04/2019	Not assessed
176					15/04/2019	16/04/2019	Not assessed
201					10/04/2019	17/04/2019	Not assessed
219					24/04/2019	30/04/2019	Not assessed
223	DQA1*01:02 negative, DQB1*06:02 negative	DQA1*01:02, DQB1*06:02			10/04/2019	16/04/2019	Acceptable
224	DQA1*01:02=NEG, DQB1*06:02=NEG				10/04/2019	17/04/2019	Acceptable
225	DQB1*06:02-negative	DQB1*06:02	The patient don't have the HLA-type that's associated with narcolepsy.		15/04/2019	17/04/2019	Acceptable
245	DQB1*02,*04	DQB1*06:02	Absence of the susceptibility allele for narcolepsy-cataplexy DQB1*06:02. This allele is present in 12 to 38% of the general population, in 40 to 60% of patients with narcolepsy without cataplexy and in 18% of patients with idiopathic hypersomnia. This result makes the diagnosis of narcolepsy-cataplexy unlikely but does not exclude the diagnosis.		10/04/2019	17/04/2019	Acceptable
255					10/04/2019	23/04/2019	Not assessed
263					18/04/2019	23/04/2019	Not assessed
269					07/04/2019	17/04/2019	Not assessed
274					12/04/2019	15/04/2019	Not assessed
276	DQB1*06:02 negative	DQB1*06:02			10/04/2019	23/04/2019	Acceptable
278					15/04/2019	25/04/2019	Not assessed
279					0000-00-00	0000-00-00	Not assessed
281	No known association with narcolepsia.	DQB1*			09/04/2019	16/04/2019	Acceptable
307					10/04/2019	12/04/2019	Not assessed
315	NEGATIVE (DQB1*02, DQB1*04)	DQB1*06:02			10/04/2019	16/04/2019	Acceptable
317					15/04/2019	17/04/2019	Not assessed
319					10/04/2019	12/04/2019	Not assessed
331	DQB1*02:01, DQB1*03:02	DQB*06:02	Absence of DQB1*06:02		12/04/2019	24/04/2019	Unacceptable
333					04/04/2019	18/04/2019	Not assessed
338					11/04/2019	28/05/2019	Not assessed
339					10/04/2019	16/04/2019	Not assessed
346					16/04/2019	23/04/2019	Not assessed
347					16/04/2019	17/04/2019	Not assessed
355					10/04/2019	30/04/2019	Not assessed
359					11/04/2019	17/04/2019	Not assessed
363					09/04/2019	16/04/2019	Not assessed
413					10/04/2019	15/04/2019	Not assessed
1350					10/04/2019	16/04/2019	Not assessed

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

801/2019	Results for assessment
ACTINIC PRURIGO	3
Total distributed	3
Total submitted	3
Reference	DRB1*08:01, DRB1*07:01
Number acceptable	3
Number unacceptable	-
Assessed <input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>

Lab	Results for assessment	Alleles of interest	Interpretative comments	Comments	Received	Tested	Assessment
11					09/04/2019	16/04/2019	Not assessed
12					10/04/2019	12/04/2019	Not assessed
15					0000-00-00	0000-00-00	Not assessed
17					11/04/2019	12/04/2019	Not assessed
24					10/04/2019	15/04/2019	Not assessed
25	DRB1*04:07 NEGATIVE	DRB1*04:07	This patient is negative for HLA DRB1*04 alleles which are associated with Actinic Prurigo		10/04/2019	18/04/2019	Acceptable
38	DRB1*08:01, *07:01	DRB1*04:07	This patient does not carry DRB1*04:07, which confers susceptibility to Actinic Prurigo		10/04/2019	18/04/2019	Acceptable
42	DRB1*07:01:07:05:07:07:10N:07:11:07:13:07:15:07:16:07:19:07:21:07:24:07:25:07:HLA-DRB1*04:07 27:07:28:07:29:07:30:07:31:07:32:07:33:07:34:07:35:07:37:07:38:07:40:07:41:07:43:0 7:45:07:46:07:47:07:48:07:49:07:51:07:52:07:53:07:55:07:56:07:58N:07:59:07:60:07:6 1:07:63:07:65:07:66:07:71:07:72:07:73:07:74:07:75:07:77:07:78:07:79:07:81:07:82:07: 84:07:85:07:86:07:87N:07:88:07:89:07:90 DRB1*08:01:08:26:08:39:08:50:08:55:08:64:08:77:08:78N:08:79:08:86		This patient is HLA-DRB1*04:07 NEGATIVE. Actinic Prurigo is associated with the expression of the human leukocyte antigen (HLA) class II molecule DRB1*04:07		11/04/2019	12/04/2019	Acceptable
78					10/04/2019	0000-00-00	Not assessed
85					10/04/2019	23/04/2019	Not assessed
86					10/04/2019	23/04/2019	Not assessed
87					10/04/2019	24/04/2019	Not assessed
109					10/04/2019	16/04/2019	Not assessed
113		Not assessed		Haemolysis of the sample. DNA concentration too low and bad quality. No result available	09/04/2019	0000-00-00	Not assessed
123					0000-00-00	0000-00-00	Not assessed
124					0000-00-00	0000-00-00	Not assessed
126					10/04/2019	15/04/2019	Not assessed
127					11/04/2019	16/04/2019	Not assessed
129					22/04/2019	23/04/2019	Not assessed
142					11/04/2019	22/04/2019	Not assessed
150					17/04/2019	18/04/2019	Not assessed
154					10/04/2019	17/04/2019	Not assessed
159					11/04/2019	12/04/2019	Not assessed
173					17/04/2019	23/04/2019	Not assessed
176					15/04/2019	16/04/2019	Not assessed
201					10/04/2019	17/04/2019	Not assessed
219					24/04/2019	30/04/2019	Not assessed
223					10/04/2019	16/04/2019	Not assessed
224					10/04/2019	17/04/2019	Not assessed
225					15/04/2019	17/04/2019	Not assessed
245	Not Tested	NT	NT		10/04/2019	17/04/2019	Not assessed
255					10/04/2019	23/04/2019	Not assessed
263					18/04/2019	23/04/2019	Not assessed
269					07/04/2019	17/04/2019	Not assessed
274					12/04/2019	15/04/2019	Not assessed
276					10/04/2019	23/04/2019	Not assessed
278					15/04/2019	25/04/2019	Not assessed
279					0000-00-00	0000-00-00	Not assessed
281					09/04/2019	16/04/2019	Not assessed
307					10/04/2019	12/04/2019	Not assessed
315					10/04/2019	16/04/2019	Not assessed
317					15/04/2019	17/04/2019	Not assessed
319					10/04/2019	12/04/2019	Not assessed
331					12/04/2019	24/04/2019	Not assessed
333					04/04/2019	18/04/2019	Not assessed
338					11/04/2019	28/05/2019	Not assessed
339					10/04/2019	16/04/2019	Not assessed
346					16/04/2019	23/04/2019	Not assessed
347					16/04/2019	17/04/2019	Not assessed
355					10/04/2019	30/04/2019	Not assessed
359					11/04/2019	17/04/2019	Not assessed
363					09/04/2019	16/04/2019	Not assessed
413					10/04/2019	15/04/2019	Not assessed
1350					10/04/2019	16/04/2019	Not assessed

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

Lab Results for assessment	Alleles of interest	Interpretative comments	Comments
801/2019 BIRDSHOT RETINOCHOROIDITIS Total distributed 7 Total submitted 7 Reference A*02, A*29 Number acceptable 7 Number unacceptable - Assessed 6	Results for assessment A*29	HLA-A allele known to be associated with but not diagnostic for birdshot chorioretinopathy is present	
11 HLA-A29 Positive	A*29		
12			
15 Not Tested			
17			
24			
25 A*29	A*29	The HLA A29 antigen associated with Birdshot Chorioretinopathy is present. The presence of a particular HLA antigen does not establish the diagnosis of any particular disease, but provides a probability statement for the possible existence of the disease in the patient.	
38 A*02, *29	A*29	This patient carries HLA-A*29 which confers susceptibility to Birdshot Retinopathy	
42 A*02:01:02:01L:02:01Q:02:07:02:09:02:15N:02:18:02:20:02:25:02:29:02:30:02:31:02:33:02:43N:02:52N:02:59:02:66:02:67:02:68:02:74:02:75:02:77:02:82N:02:83N:02:85:02:86:02:89:02:93:02:94N:02:95:02:96:02:97:02:101:02:102:107:02:108:02:116:02:121:02:132:02:133:02:134:02:138:02:140:02:150:02:153:02:158:02:160:02:161:02:162:02:164:02:165:02:166:02:167:02:168:02:173:02:175:02:176:02:177:02:181:02:182:02:187:02:189:02:192:02:194:02:197:02:198:02:200:02:201:02:202:02:203:02:205:02:206:02:207:02:208:02:211:02:214:02:216:02:218:02:219:02:220:02:221:02:225N:02:226N:02:227N:02:228:02:231:02:233:02:235:02:236:02:238:02:240:02:241:02:242:02:252:02:256:02:257:02:262:02:263:02:265:02:266:02:268:02:272:02:273:02:275:02:277:02:282:02:283:02:284N:02:285:02:286:02:291:02:293Q:02:294:02:296:02:299:02:301N:02:302:02:309N:02:306:02:307:02:311:02:318:02:321N:02:325:02:326:02:327:02:328:02:332:02:334:02:336:02:338:02:340:02:342:02:343:02:346:02:347:02:350N:02:352:02:354:02:356N:02:357:02:360:02:361:02:362:02:363:02:364:02:368:02:369:02:370:02:376:02:372:02:375:02:377:02:378:02:381:02:383:02:384:02:385:02:388:02:389:02:390:02:391:02:392:02:395N:02:396:02:397:02:401:02:403:02:407:02:411:02:414:02:418:02:419:02:422:02:424:02:425:02:426:02:427:02:432:02:434:02:435:02:437:02:439N:02:440:02:441:02:442:02:445:02:448:02:449:02:450:02:452:02:455:02:456:02:458:02:459:02:460:02:461:02:462:02:464:02:467:02:468N:02:469:02:477:02:478:02:481:02:482:02:483:02:486:02:488:02:491:02:498:02:500Q:02:501N:02:502:02:504:02:508:02:513:02:516N:02:518:02:519:02:521:02:522:02:523:02:524:02:525N:02:530:02:533:02:535:02:538:02:539:02:540N:02:547:02:548:02:551:02:552:02:553:02:554:02:559:02:560:02:564:02:566:02:569:02:567:02:568:02:573:02:576:02:581:02:582:02:586:02:587:02:588:02:589:02:610:02:620:02:700:02:708: A*29:02:29:06:29:10:29:11:29:21:29:22:29:23:29:26:29:27:29:29:29:30:29:36:29:42:29:43:29:44:29:49:29:50:29:52:29:53:29:54:29:55:29:53:29:65:29:66:29:68:29:70:29:72:29:75:29:78N:29:88:29:91:29:94:29:95:29:96:29:100:29:102:29:103:29:106:29:108:29:111:29:112N			
76			
85			
86			
87			
109			
113	Not assessed		Haemolysis of the sample. DNA concentration too low and bad quality. No result available
123			
124			
126			
127			
129			
142			
150 A*02:29	A*29	Presence of allele A*29.	
154			
159			
173			
176			
201			
219			
223			
224			
225			
245 A*02,*29	A*29	Presence of the A*29 susceptibility allele. The presence of the A*29 allele, associated with the clinical signs of the disease, is strongly in favor of the diagnosis of birdshot disease. The prevalence of A*29 in patients with birdshot is 90 to 100% according to published studies.	
255			
263			
269			
274			
276			
278			
279			
281			
307			
315 POSITIVE (A*02, A*29)	A*29		
317			
319			
331			
333			
338			
339			
346			
347			
355			
359			
363			
413			
1350			

Received	Tested	Assessment
09/04/2019	16/04/2019	Acceptable
10/04/2019	12/04/2019	Not assessed
0000-00-00	0000-00-00	Not assessed
11/04/2019	12/04/2019	Not assessed
10/04/2019	15/04/2019	Not assessed
10/04/2019	18/04/2019	Acceptable
10/04/2019	18/04/2019	Acceptable
11/04/2019	12/04/2019	Acceptable
10/04/2019	0000-00-00	Not assessed
10/04/2019	23/04/2019	Not assessed
10/04/2019	23/04/2019	Not assessed
10/04/2019	24/04/2019	Not assessed
10/04/2019	16/04/2019	Not assessed
09/04/2019	0000-00-00	Not assessed
0000-00-00	0000-00-00	Not assessed
0000-00-00	0000-00-00	Not assessed
10/04/2019	15/04/2019	Not assessed
11/04/2019	16/04/2019	Not assessed
22/04/2019	29/04/2019	Not assessed
11/04/2019	22/04/2019	Not assessed
17/04/2019	16/04/2019	Acceptable
10/04/2019	17/04/2019	Not assessed
11/04/2019	12/04/2019	Not assessed
17/04/2019	23/04/2019	Not assessed
15/04/2019	16/04/2019	Not assessed
10/04/2019	17/04/2019	Not assessed
24/04/2019	30/04/2019	Not assessed
10/04/2019	16/04/2019	Not assessed
10/04/2019	17/04/2019	Not assessed
10/04/2019	17/04/2019	Acceptable
10/04/2019	23/04/2019	Not assessed
18/04/2019	23/04/2019	Not assessed
07/04/2019	17/04/2019	Not assessed
12/04/2019	15/04/2019	Not assessed
10/04/2019	23/04/2019	Not assessed
15/04/2019	25/04/2019	Not assessed
0000-00-00	0000-00-00	Not assessed
09/04/2019	16/04/2019	Not assessed
10/04/2019	12/04/2019	Not assessed
10/04/2019	16/04/2019	Acceptable
15/04/2019	17/04/2019	Not assessed
10/04/2019	12/04/2019	Not assessed
12/04/2019	24/04/2019	Not assessed
04/04/2019	18/04/2019	Not assessed
11/04/2019	28/05/2019	Not assessed
10/04/2019	16/04/2019	Not assessed
16/04/2019	23/04/2019	Not assessed
16/04/2019	17/04/2019	Not assessed
10/04/2019	30/04/2019	Not assessed
11/04/2019	17/04/2019	Not assessed
09/04/2019	16/04/2019	Not assessed
10/04/2019	15/04/2019	Not assessed
10/04/2019	16/04/2019	Not assessed

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

Lab	Results for assessment	Alleles of interest	Interpretative comments	Comments	Received	Tested	Assessment
801/2019	BEHCETS_DISEASE						
	Results for assessment						
	Total distributed	12					
	Total submitted	12					
	Reference	B*44, B*51					
	Number acceptable	10					
	Number unacceptable	-					
	Assessed	12					
11	HLA-B*51 Positive	B*51	HLA-B*51(5) is associated with but is not diagnostic for Behcet's disease		09/04/2019	16/04/2019	Acceptable
12	HLA-B*51: Positive	HLA-B*51	This patient is positive for HLA-B*51 (the HLA specificity associated with Behcet's disease).		10/04/2019	12/04/2019	Acceptable
			HLA-B*51 is present in approximately 9% of the normal Caucasian population.				
15	Not Tested				0000-00-00	0000-00-00	Not assessed
17					11/04/2019	12/04/2019	Not assessed
24					10/04/2019	15/04/2019	Not assessed
25	B*51	B*51	The HLA B51 antigen associated with Behcet's Disease is present. The presence of a particular HLA antigen does not establish the diagnosis of any particular disease, but provides a probability statement for the possible existence of the disease in the patient.		10/04/2019	18/04/2019	Acceptable
			This patient carries HLA-B*51 which confers susceptibility to Behcet's disease.				
			This patient is HLA-B*51 POSITIVE. Behcet's disease is associated with the expression of the human leukocyte antigen (HLA) class I molecule B51.		11/04/2019	12/04/2019	Acceptable
38	HLA-B*44,*51	B*51			10/04/2019	18/04/2019	Acceptable
42	B*44.03/44.26/44.35/44.36/44.38/44.39/44.47/44.79/44.85/44.88/44.94/44.98/44.103/44.108/44.111/44.115/44.116/44.122/44.125/44.128/44.141/44.147/44.154/44.155/44.157/44.159/44.161/44.164/44.165/44.167/44.175/44.178/44.180/44.182/44.183/44.184/44.186/44.188/44.192/44.198/44.202/44.205/44.207/44.222/44.228/44.231/44.233/44.237/44.239/44.250/44.252/44.258/44.278/44.280/44.281/44.284/44.286	B*51			10/04/2019	18/04/2019	Acceptable
	B*51.01/51.02/51.04/51.09/51.11/51.12/51.14/51.15/51.16/51.17/51.18/51.19/51.20/51.21/51.22/51.23/51.24/51.25/51.26/51.27/51.28/51.29/51.30/51.31/51.32/51.33/51.34/51.35/51.36/51.38/51.39/51.41/51.42/51.43/51.44/51.45/51.46/51.47/51.48/51.49/51.50/51.51/51.52/51.53/51.54/51.55/51.56/51.57/51.58/51.59/51.60/51.61/51.62/51.63/51.64/51.65/51.66/51.67/51.68/51.69/51.70/51.71/51.72/51.73/51.74/51.75/51.76/51.77/51.78/51.79/51.80/51.81/51.82/51.83/51.84/51.85/51.86/51.87/51.88/51.89/51.90/51.91/51.92/51.93/51.94/51.95/51.96/51.97/51.98/51.99/51.100/51.101/51.102/51.103/51.104/51.105/51.106/51.107/51.108/51.109/51.110/51.111/51.112/51.113/51.114/51.115/51.116/51.117/51.118/51.119/51.120/51.121/51.122/51.123/51.124/51.125/51.126/51.127/51.128/51.129/51.130/51.131/51.132/51.133/51.134/51.135/51.136/51.137/51.138/51.139/51.140/51.141/51.142/51.143/51.144/51.145/51.146/51.147/51.148/51.149/51.150/51.151/51.152/51.153/51.154/51.155/51.156/51.157/51.158/51.159/51.160/51.161/51.162/51.163/51.164/51.165/51.166/51.167/51.168/51.169/51.170/51.171/51.172/51.173/51.174/51.175/51.176/51.177/51.178/51.179/51.180/51.181/51.182/51.183/51.184/51.185/51.186/51.187/51.188/51.189/51.190/51.191/51.192/51.193/51.194/51.195/51.196/51.197/51.198/51.199/51.200/51.201/51.202/51.203/51.204/51.205/51.206/51.207/51.208/51.209/51.210/51.211/51.212/51.213/51.214/51.215/51.216/51.217/51.218/51.219/51.220/51.221/51.222/51.223/51.224/51.225/51.226/51.227/51.228/51.229/51.230/51.231/51.232/51.233/51.234/51.235/51.236/51.237/51.238/51.239/51.240/51.241/51.242/51.243/51.244/51.245/51.246/51.247/51.248/51.249/51.250	B*51			10/04/2019	0000-00-00	Not assessed
78	Not tested				10/04/2019	23/04/2019	Not assessed
85					10/04/2019	23/04/2019	Not assessed
86					10/04/2019	23/04/2019	Not assessed
87					10/04/2019	24/04/2019	Not assessed
109					10/04/2019	16/04/2019	Not assessed
113	Haemolysis of the sample. No result available	B51		Haemolysis of the sample. DNA concentration too low and bad quality. No result available	09/04/2019	0000-00-00	Not assessed
123					0000-00-00	0000-00-00	Not assessed
124					0000-00-00	0000-00-00	Not assessed
126					10/04/2019	15/04/2019	Not assessed
127					11/04/2019	16/04/2019	Not assessed
129					22/04/2019	29/04/2019	Not assessed
142	HLA-B*51 present	HLA-B*51	Presence of allele B*51.		11/04/2019	22/04/2019	Acceptable
150	B*44,*51	B*51			17/04/2019	18/04/2019	Acceptable
154					10/04/2019	17/04/2019	Not assessed
159					11/04/2019	12/04/2019	Not assessed
173	HLA-B*51 POSITIVE	HLA-B*51	High risk of Behçet Syndrome		17/04/2019	23/04/2019	Acceptable
176					15/04/2019	16/04/2019	Not assessed
201					10/04/2019	17/04/2019	Not assessed
219					24/04/2019	30/04/2019	Not assessed
223					10/04/2019	16/04/2019	Not assessed
224					10/04/2019	17/04/2019	Not assessed
225					15/04/2019	17/04/2019	Not assessed
245	B*44,*51	B*51	Presence of the susceptibility allele HLA-B*51. The presence of this allele confers on the wearer a risk multiplied by 6 to develop a Behçet disease compared to the general population. 30-60% of affected patients have this allele. This result alone does not support the diagnosis of Behçet's disease. It must be associated with other clinico-biological signs corresponding to the diagnostic criteria.		10/04/2019	17/04/2019	Acceptable
255					10/04/2019	23/04/2019	Not assessed
263					18/04/2019	23/04/2019	Not assessed
269					07/04/2019	17/04/2019	Not assessed
274					12/04/2019	15/04/2019	Not assessed
276					10/04/2019	23/04/2019	Not assessed
278					15/04/2019	25/04/2019	Not assessed
279					0000-00-00	0000-00-00	Not assessed
281					09/04/2019	16/04/2019	Not assessed
307					10/04/2019	12/04/2019	Not assessed
315	POSITIVE (B*44, B*51)	B*51			10/04/2019	16/04/2019	Acceptable
317					15/04/2019	17/04/2019	Not assessed
319					10/04/2019	12/04/2019	Not assessed
331					12/04/2019	24/04/2019	Not assessed
333					04/04/2019	18/04/2019	Not assessed
338					11/04/2019	28/05/2019	Not assessed
339					10/04/2019	16/04/2019	Not assessed
346					16/04/2019	23/04/2019	Not assessed
347					16/04/2019	17/04/2019	Not assessed
355					10/04/2019	30/04/2019	Not assessed
359					11/04/2019	17/04/2019	Not assessed
363					09/04/2019	16/04/2019	Not assessed
413					10/04/2019	15/04/2019	Not assessed
1350					10/04/2019	16/04/2019	Not assessed

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

801/2019	Results for assessment
RHEUMATOID ARTHRITIS	2
Total distributed	2
Total submitted	2
<u>Reference</u>	DRB1*08:01, DRB1*07:01
Number acceptable	1
Number unacceptable	-
<u>Assessed</u> <input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>

Lab	Results for assessment	Alleles of interest	Interpretative comments	Comments	Received	Tested	Assessment
11					09/04/2019	16/04/2019	Not assessed
12					10/04/2019	12/04/2019	Not assessed
15					0000-00-00	0000-00-00	Not assessed
17					11/04/2019	12/04/2019	Not assessed
24					10/04/2019	15/04/2019	Not assessed
25					10/04/2019	18/04/2019	Not assessed
38					10/04/2019	18/04/2019	Not assessed
42					11/04/2019	12/04/2019	Not assessed
78					10/04/2019	0000-00-00	Not assessed
85					10/04/2019	23/04/2019	Not assessed
86					10/04/2019	23/04/2019	Not assessed
87					10/04/2019	24/04/2019	Not assessed
109					10/04/2019	16/04/2019	Not assessed
113	Haemolysis of the sample. No result available	DRB1*01:01, DRB1*01:02, DRB1*04:01, DRB1*04:04, DRB1*04:05, DRB1*04:08, DRB1*04:09, DRB1*04:10, DRB1*10, DRB1*14:02, DRB1*14:06		Haemolysis of the sample. DNA concentration too low and bad quality. No result available	09/04/2019	0000-00-00	Not assessed
123					0000-00-00	0000-00-00	Not assessed
124					0000-00-00	0000-00-00	Not assessed
126					10/04/2019	15/04/2019	Not assessed
127					11/04/2019	16/04/2019	Not assessed
129					22/04/2019	29/04/2019	Not assessed
142					11/04/2019	22/04/2019	Not assessed
150					17/04/2019	18/04/2019	Not assessed
154					10/04/2019	17/04/2019	Not assessed
159					11/04/2019	12/04/2019	Not assessed
173					17/04/2019	23/04/2019	Not assessed
176					15/04/2019	16/04/2019	Not assessed
201					10/04/2019	17/04/2019	Not assessed
219					24/04/2019	30/04/2019	Not assessed
223					10/04/2019	16/04/2019	Not assessed
224					10/04/2019	17/04/2019	Not assessed
225					15/04/2019	17/04/2019	Not assessed
245	DRB1*07,*08	DRB1*04:01,*04:04,*04:05,*04:08 DRB1*10 DRB1*01:01,*01:02,*01:04 DRB1*14:06	No single or double dose shared epitope. The patient has no shared epitopes associated with a risk of developing rheumatoid arthritis. 20% of patients with rheumatoid arthritis do not have a shared epitope, so this result does not eliminate the diagnosis.		10/04/2019	17/04/2019	Acceptable
255					10/04/2019	23/04/2019	Not assessed
263					18/04/2019	23/04/2019	Not assessed
269					07/04/2019	17/04/2019	Not assessed
274					12/04/2019	15/04/2019	Not assessed
276					10/04/2019	23/04/2019	Not assessed
278					15/04/2019	25/04/2019	Not assessed
279					0000-00-00	0000-00-00	Not assessed
281					09/04/2019	16/04/2019	Not assessed
307					10/04/2019	12/04/2019	Not assessed
315					10/04/2019	16/04/2019	Not assessed
317					15/04/2019	17/04/2019	Not assessed
319					10/04/2019	12/04/2019	Not assessed
331	DRB1*07, DRB1*08	DRB1*04	Absence of DRB1*04		12/04/2019	24/04/2019	Not assessed
333					04/04/2019	18/04/2019	Not assessed
338					11/04/2019	28/05/2019	Not assessed
339					10/04/2019	16/04/2019	Not assessed
346					16/04/2019	23/04/2019	Not assessed
347					16/04/2019	17/04/2019	Not assessed
355					10/04/2019	30/04/2019	Not assessed
359					11/04/2019	17/04/2019	Not assessed
363					09/04/2019	16/04/2019	Not assessed
413					10/04/2019	15/04/2019	Not assessed
1350					10/04/2019	16/04/2019	Not assessed

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

801/2019	Results for assessment
DIABETES	5
Total distributed	5
Total submitted	5
Reference	DRB1*08:01,*07:01,DQA1*02:01,*04:01,DQB1*02:02,*04:02
Number acceptable	4
Number unacceptable	-
Assessed @	2

Lab	Results for assessment	Alleles of interest	Interpretative comments	Comments	Received	Tested	Assessment
11					09/04/2019	16/04/2019	Not assessed
12					10/04/2019	12/04/2019	Not assessed
15					0000-00-00	0000-00-00	Not assessed
17					11/04/2019	12/04/2019	Not assessed
24					10/04/2019	15/04/2019	Not assessed
25					10/04/2019	18/04/2019	Not assessed
38					10/04/2019	18/04/2019	Not assessed
42					11/04/2019	12/04/2019	Not assessed
78					10/04/2019	0000-00-00	Not assessed
85					10/04/2019	23/04/2019	Not assessed
86					10/04/2019	23/04/2019	Not assessed
87					10/04/2019	24/04/2019	Not assessed
109					10/04/2019	16/04/2019	Not assessed
113	Haemolysis of the sample. No result available	DRB1*04:DQA1*03:01:DQB1*03:02, DRB1*03:01:DQA1*05:01:DQB1*02:01		Haemolysis of the sample. DNA concentration too low and bad quality. No result available	09/04/2019	0000-00-00	Not assessed
123					0000-00-00	0000-00-00	Not assessed
124					0000-00-00	0000-00-00	Not assessed
126					10/04/2019	15/04/2019	Not assessed
127					11/04/2019	16/04/2019	Not assessed
129	DQB1*02,*04,DQA1*02:01	DQB1*02,*03:01,*03:02,*03:03,*03:04,*04,*05:01,*05:03,*06:01,*06:02,*06:03,*06:04 DQA1*02:01,*03,*05 DRB1*04:01,*04:02,*04:03/6,*04:04,*04:05,*04:07	Neutral risk (no risk or protection associated haplotypes)		22/04/2019	29/04/2019	Acceptable
142					11/04/2019	22/04/2019	Not assessed
150	DRB1*07:08	DR3 : DRB1*03:01 - DR4 : DRB1*04:05	Absence of alleles DR3 OR DR4.		17/04/2019	18/04/2019	Acceptable
154	HLA-DRB1*07,*08; HLA-DQA1*02:01,*04:01; HLA-DQB1*02:02,*04:02	HLA-DRB1* is typed to the 2-digit level and HLA-DQA1* and HLA-DQB1* are typed to the 4-digit level to detect the following haplotypes : HLA-DRB1*03,DQA1*05:01,DQB1*02:01 and HLA-DRB1*04,DQA1*03:01,DQB1*03:02	haplotype DR3.DQ2 (DRB1*03.DQA1*05:01.DQB1*02:01) : absence haplotype DR4.DQ8 (DRB1*04.DQA1*03:01.DQB1*03:02) : absence The patient has no HLA haplotype associated with type 1 diabetes. The DR3.DQ2 and DR4.DQ8 haplotypes are found in 95% of type 1 diabetes patients. The HLA-DR3 and DR4 antigens are found 40% of the Caucasian population.		10/04/2019	17/04/2019	Acceptable
159					11/04/2019	12/04/2019	Not assessed
173					17/04/2019	23/04/2019	Not assessed
176					15/04/2019	16/04/2019	Not assessed
201					10/04/2019	17/04/2019	Not assessed
219					24/04/2019	30/04/2019	Not assessed
223					10/04/2019	16/04/2019	Not assessed
224					10/04/2019	17/04/2019	Not assessed
225					15/04/2019	17/04/2019	Not assessed
245	DRB1*07,*08,DQA1*02,*04,DQB1*02,*04	Susceptible: DRB1*03:01:DQA1*05:01:DQB1*02:01 DRB1*04:01:DQA1*03:01:DQB1*03:02/04 DRB1*04:02:DQA1*03:01:DQB1*03:02/04 DRB1*04:04:DQA1*03:01:DQB1*03:02/04 DRB1*04:05:DQA1*03:01:DQB1*03:02/04 Protector: DRB1*15:01:DQA1*01:02:DQB1*06:02 DRB1*14:01:DQA1*01:01:DQB1*05:03 DRB1*07:01:DQA1*02:01:DQB1*03:03 DRB1*04:03:DQA1*03:01:DQB1*03:02	Absence of alleles that may constitute a susceptibility or protective HLA haplotype to type 1 diabetes. This result does not constitute a criterion for excluding the disease.		10/04/2019	17/04/2019	Acceptable
255					10/04/2019	23/04/2019	Not assessed
263					18/04/2019	23/04/2019	Not assessed
269					07/04/2019	17/04/2019	Not assessed
274					12/04/2019	15/04/2019	Not assessed
276					10/04/2019	23/04/2019	Not assessed
278					15/04/2019	25/04/2019	Not assessed
279					0000-00-00	0000-00-00	Not assessed
281					09/04/2019	16/04/2019	Not assessed
307					10/04/2019	12/04/2019	Not assessed
315					10/04/2019	16/04/2019	Not assessed
317					15/04/2019	17/04/2019	Not assessed
319					10/04/2019	12/04/2019	Not assessed
331	DRB1*07, DRB1*08	DRB1*03, DRB1*04	Absence of DRB1*03 ; Absence of DRB1*04		12/04/2019	24/04/2019	Not assessed
333					04/04/2019	18/04/2019	Not assessed
338					11/04/2019	28/05/2019	Not assessed
339					10/04/2019	16/04/2019	Not assessed
346					16/04/2019	23/04/2019	Not assessed
347					16/04/2019	17/04/2019	Not assessed
355					10/04/2019	30/04/2019	Not assessed
359					11/04/2019	17/04/2019	Not assessed
363					09/04/2019	16/04/2019	Not assessed
413					10/04/2019	15/04/2019	Not assessed
1350					10/04/2019	16/04/2019	Not assessed

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

801/2019	Results for assessment
OTHER	0
Total distributed	0
Total submitted	0
Reference	-
Number acceptable	-
Number unacceptable	-
Assessed <input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>

Lab	Results for assessment	Alleles of interest	Interpretative comments	Comments	Received	Tested	Assessment
11					09/04/2019	16/04/2019	Not assessed
12					10/04/2019	12/04/2019	Not assessed
15					0000-00-00	0000-00-00	Not assessed
17					11/04/2019	12/04/2019	Not assessed
24					10/04/2019	15/04/2019	Not assessed
25					10/04/2019	18/04/2019	Not assessed
38					10/04/2019	18/04/2019	Not assessed
42					11/04/2019	12/04/2019	Not assessed
78					10/04/2019	0000-00-00	Not assessed
85					10/04/2019	23/04/2019	Not assessed
86					10/04/2019	23/04/2019	Not assessed
87					10/04/2019	24/04/2019	Not assessed
109					10/04/2019	16/04/2019	Not assessed
113				Haemolysis of the sample. DNA concentration too low and bad quality. No result available	09/04/2019	0000-00-00	Not assessed
123					0000-00-00	0000-00-00	Not assessed
124					0000-00-00	0000-00-00	Not assessed
126					10/04/2019	15/04/2019	Not assessed
127					11/04/2019	18/04/2019	Not assessed
129					22/04/2019	29/04/2019	Not assessed
142					11/04/2019	22/04/2019	Not assessed
150					17/04/2019	18/04/2019	Not assessed
154					10/04/2019	17/04/2019	Not assessed
159					11/04/2019	12/04/2019	Not assessed
173					17/04/2019	23/04/2019	Not assessed
176					15/04/2019	16/04/2019	Not assessed
201					10/04/2019	17/04/2019	Not assessed
219					24/04/2019	30/04/2019	Not assessed
223					10/04/2019	16/04/2019	Not assessed
224					10/04/2019	17/04/2019	Not assessed
225					15/04/2019	17/04/2019	Not assessed
245					10/04/2019	17/04/2019	Not assessed
255					10/04/2019	23/04/2019	Not assessed
263					18/04/2019	23/04/2019	Not assessed
269					07/04/2019	17/04/2019	Not assessed
274					12/04/2019	15/04/2019	Not assessed
276					10/04/2019	23/04/2019	Not assessed
278					15/04/2019	25/04/2019	Not assessed
279					0000-00-00	0000-00-00	Not assessed
281					09/04/2019	16/04/2019	Not assessed
307					10/04/2019	12/04/2019	Not assessed
315					10/04/2019	16/04/2019	Not assessed
317					15/04/2019	17/04/2019	Not assessed
319					10/04/2019	12/04/2019	Not assessed
331					12/04/2019	24/04/2019	Not assessed
333					04/04/2019	18/04/2019	Not assessed
338					11/04/2019	28/05/2019	Not assessed
339					10/04/2019	16/04/2019	Not assessed
346					16/04/2019	23/04/2019	Not assessed
347					16/04/2019	17/04/2019	Not assessed
355					10/04/2019	30/04/2019	Not assessed
359					11/04/2019	17/04/2019	Not assessed
363					09/04/2019	16/04/2019	Not assessed
413					10/04/2019	15/04/2019	Not assessed
1350					10/04/2019	16/04/2019	Not assessed